Next Article in Journal
Use of Bacterial Extracellular Vesicles for Gene Delivery to Host Cells
Next Article in Special Issue
Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases
Previous Article in Journal
Galectins Differentially Regulate the Surface Glycosylation of Human Monocytes
Previous Article in Special Issue
Angiotensin II-Induced Vasoconstriction via Rho Kinase Activation in Pressure-Overloaded Rat Thoracic Aortas
 
 
Article
Peer-Review Record

Renin-a in the Subfornical Organ Plays a Critical Role in the Maintenance of Salt-Sensitive Hypertension

Biomolecules 2022, 12(9), 1169; https://doi.org/10.3390/biom12091169
by Silvana G. Cooper 1,2, Lucas A. C. Souza 1,2, Caleb J. Worker 1,2, Ariana Julia B. Gayban 1,2, Sophie Buller 3, Ryosuke Satou 4 and Yumei Feng Earley 1,2,*
Reviewer 1: Anonymous
Reviewer 2:
Biomolecules 2022, 12(9), 1169; https://doi.org/10.3390/biom12091169
Submission received: 1 August 2022 / Revised: 20 August 2022 / Accepted: 22 August 2022 / Published: 24 August 2022
(This article belongs to the Special Issue Renin-Angiotensin System in Diseases)

Round 1

Reviewer 1 Report

In the manuscript by Cooper and colleagues, the authors investigated the hypothesis that renin-a produced locally in the brain contributes to the pathogenesis of hypertension using a DOCA-salt hypertension model. The overall conclusions of findings demonstrate that endogenous renin-a within the SFO is important for the pathogenesis of salt-sensitive hypertension. The experiments were conducted with proper controls, manuscript was well written, and the conclusions were well drawn. Below are few comments:

1.     Figure 1. The total renin levels were detected in different brain regions at the end of the DOCA-salt hypertension paradigm suggest that the association of increased mRNA with hypertension. However, when this increase is happening and does this increase in mRNA correlates with the increase in blood pressure during the time-course of DOCA-salt treatment?

2.     Figure 3. Figure 3C is missing.

3.     Figure 5A. SFO targeted AAV2 injections were performed 1 week prior to DOCA-salt hypertension. When will be the highest/peak expression of target gene (or knockdown of target gene) is achieved? Does one week prior is sufficient? Figure 4 was shown after 4 weeks. Does injecting AAV2 2 weeks prior to DOCA-salt will influence the effect on blood pressure?

4.     Figure 5C. The MAP was significantly different at the end of 21 days. However, please show the statistical difference at each day.

5.     Figure 6. The dose of DOCA was used in the present study is high according to authors. Does DOCA dose will influence the outcome of the present study?

6.     What is the contribution of Renin-a to the over all renin activity in the brain?

Author Response

We thank the reviewer for their constructive comments, which have helped to improve our manuscript. All questions and concerns are addressed in a point-by-point manner. Please see the attachment. 

Author Response File: Author Response.pdf

Reviewer 2 Report

Figure 3 should include an image of an entire brain slice with labeling in addition to the already shown higher zoom GFP image.

Figure 5B: it looks like there is significance between the blue and orange lines early in administration of NaCl

Figures using viral injections should include images of injection sites.

Figure 9c should include DOCA

Author Response

We thank the reviewer for their constructive comments, which have helped to improve our manuscript. All questions and concerns are addressed in a point-by-point manner. Please see the attachment. 

Author Response File: Author Response.pdf

Back to TopTop